Outsourcing Next-Gen Therapies Relies on Expertise and Technology: The value of outsourcing partnerships for next-gen biotherapeutics rests in the expertise and technologies that service providers bring to the table.
| Published in: | BioPharm International Vol. 38; pp. 4 - 8 |
|---|---|
| Main Author: | |
| Format: | pictorial Journal Article |
| Published: |
MJH Life Sciences
2025 Special Issue
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183584335&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 183584335 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1542166X 5NE jtl: BioPharm International issn: 1542166X maglogo: N pubinfo: dt: 2025 Special Issue vid: 38 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 183584335 183584335 183584335 183584335 ppf: 4 ppct: 4 formats: fmt: @attributes: type: P tig: atl: Outsourcing Next-Gen Therapies Relies on Expertise and Technology: The value of outsourcing partnerships for next-gen biotherapeutics rests in the expertise and technologies that service providers bring to the table. aug: au: Mirasol, Feliza sug: subj: Biological Therapy Methods Gene Therapy Antibodies, Monoclonal Drug Development Manufacturing Industry Contract Services Technology Nucleic Acids Therapeutic Use COVID-19 Vaccines RNA Gene Expression Cost Effectiveness Analysis pubtype: Trade Publication doctype: pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|